<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.03">
 <iati-activity default-currency="GBP" hierarchy="1" humanitarian="0" iati-activities:version="2.03" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities">
  <iati-identifier>GB-GOV-10-PDP_GARDP_NS</iati-identifier>
  <reporting-org ref="GB-GOV-10" type="10">
   <narrative xml:lang="EN">UK - Department of Health and Social Care (DHSC)</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">Global Antibiotic Research and Development Partnership&#x2019;s Neonatal Sepsis Programme (GARDP) support</narrative>
  </title>
  <description type="1">
   <narrative xml:lang="EN">A partnership to fund the development of new treatments for severe bacterial infections in neonates under GARDP&#x2019;s Neonatal Sepsis Programme</narrative>
  </description>
  <description type="2">
   <narrative xml:lang="EN">The overall purpose of GARDP&#x2019;s neonatal sepsis programme is to develop up to three new or improved treatments for newborns with severe bacterial infections by 2023. The activities funded under this programme will make an important contribution towards achieving these objectives by prioritising three work packages with the following focus:
1. Improve clinical management of neonatal sepsis
This work package includes three key activities: completion of the global observational study; commencing clinical programme to develop a treatment to be used in place of the current WHO recommended empiric treatment, ampicillin and gentamicin for neonatal sepsis, and conducting clinical and laboratory capability strengthening in support of the clinical programme.
2. Developing new and improved treatments for multi drug-resistant infections in neonates
This work package will aim to develop an effective and safe treatment for confirmed or highly suspected MDR-GN pathogens, including K. pneumoniae, or Acinetobacter spp., that is affordable and adapted for use in neonates.
3. Accelerating regulatory approval and access in high burden LMICs
Through this work package, GARDP will work with WHO, pharmaceutical companies and regulatory authorities to ensure the newly developed treatments are globally accessible and that they are not &#x2018;lost&#x2019; to resistance within a few years after their introduction. To achieve this, GARDP, in partnership with the relevant partner(s), will develop regulatory, public health and market access (including supply and distribution) strategies for any treatments developed.</narrative>
  </description>
  <participating-org role="4" type="30">
   <narrative xml:lang="EN">Global Antibiotic Research and Development Partnership</narrative>
  </participating-org>
  <participating-org ref="GB-GOV-10" role="1" type="10">
   <narrative xml:lang="EN">UK - Department of Health and Social Care (DHSC)</narrative>
  </participating-org>
  <participating-org ref="GB-GOV-10" role="2" type="10">
   <narrative xml:lang="EN">UK - Department of Health and Social Care (DHSC)</narrative>
  </participating-org>
  <participating-org ref="GB-GOV-10" role="3" type="10">
   <narrative xml:lang="EN">UK - Department of Health and Social Care (DHSC)</narrative>
  </participating-org>
  <activity-status code="2"></activity-status>
  <activity-date iso-date="2020-03-01" type="1"></activity-date>
  <activity-date iso-date="2020-03-01" type="2"></activity-date>
  <activity-date iso-date="2021-03-31" type="4"></activity-date>
  <contact-info type="1">
   <organisation>
    <narrative xml:lang="EN">UK - Department of Health and Social Care (DHSC)</narrative>
   </organisation>
   <department>
    <narrative xml:lang="EN">Science, Research and Evidence</narrative>
   </department>
   <person-name>
    <narrative xml:lang="EN">Global Health Research Programme</narrative>
   </person-name>
   <email>GlobalHealthResearch@dhsc.gov.uk</email>
   <website>https://www.nihr.ac.uk/funding-and-support/global-health-research/</website>
   <mailing-address>
    <narrative xml:lang="EN">7th Floor South Wing, 39 Victoria Street, London, SW1H 0EU</narrative>
   </mailing-address>
  </contact-info>
  <recipient-region code="998" percentage="100" vocabulary="1"></recipient-region>
  <sector code="12182" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">Medical research</narrative>
  </sector>
  <collaboration-type code="1"></collaboration-type>
  <default-flow-type code="10"></default-flow-type>
  <default-finance-type code="110"></default-finance-type>
  <default-aid-type code="C01" vocabulary="1"></default-aid-type>
  <default-tied-status code="5"></default-tied-status>
  <budget status="1" type="1">
   <period-start iso-date="2019-04-01"></period-start>
   <period-end iso-date="2020-03-31"></period-end>
   <value currency="GBP" value-date="2020-03-01">2164656</value>
  </budget>
  <budget status="1" type="1">
   <period-start iso-date="2020-04-01"></period-start>
   <period-end iso-date="2021-03-31"></period-end>
   <value currency="GBP" value-date="2020-03-01">1835344</value>
  </budget>
  <capital-spend percentage="100"></capital-spend>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2019-12-13"></transaction-date>
   <value currency="GBP" value-date="2019-12-13">2164656</value>
   <description>
    <narrative xml:lang="EN">GB-GOV-10-PDP_GARDP_NS 2019/20 Q3 DISBURSEMENT</narrative>
   </description>
   <provider-org provider-activity-id="GB-GOV-10-PDP_GARDP_NS" ref="GB-GOV-10">
    <narrative xml:lang="EN">UK - Department of Health and Social Care (DHSC)</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">Global Antibiotic Research and Development Partnership</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2020-06-26"></transaction-date>
   <value currency="GBP" value-date="2020-06-26">783474</value>
   <description>
    <narrative xml:lang="EN">GB-GOV-10-PDP_GARDP_NS 2020/21 Q1 DISBURSEMENT</narrative>
   </description>
   <provider-org provider-activity-id="GB-GOV-10-PDP_GARDP_NS" ref="GB-GOV-10">
    <narrative xml:lang="EN">UK - Department of Health and Social Care (DHSC)</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">Global Antibiotic Research and Development Partnership</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2020-11-27"></transaction-date>
   <value currency="GBP" value-date="2020-11-27">1051870</value>
   <description>
    <narrative xml:lang="EN">GB-GOV-10-PDP_GARDP_NS 2020/21 Q3 DISBURSEMENT</narrative>
   </description>
   <provider-org provider-activity-id="GB-GOV-10-PDP_GARDP_NS" ref="GB-GOV-10">
    <narrative xml:lang="EN">UK - Department of Health and Social Care (DHSC)</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">Global Antibiotic Research and Development Partnership</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2019-12-05"></transaction-date>
   <value currency="GBP" value-date="2019-12-05">4000000</value>
   <description>
    <narrative xml:lang="EN">GB-GOV-10-PDP_GARDP_NS COMMITMENT</narrative>
   </description>
   <provider-org provider-activity-id="GB-GOV-10-PDP_GARDP_NS" ref="GB-GOV-10">
    <narrative xml:lang="EN">UK - Department of Health and Social Care (DHSC)</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">Global Antibiotic Research and Development Partnership</narrative>
   </receiver-org>
  </transaction>
  <conditions attached="0"></conditions>
 </iati-activity>
</iati-activities>
